Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) and Elevated Alanine Aminotransferase (ALT)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.

Who May Be Eligible (Plain English)

Who May Qualify: Inclusion Criteria for all patients: 1. Age 18-75 years 2. A clinical diagnosis of non-alcoholic fatty liver disease. 3. Alanine aminotransferase (ALT) levels ≥60 IU/mL 4. Laboratory tests as defined below: - Platelets \> 100,000/dL - Total bilirubin \< 2 mg/dL - Creatinine \< 1.6 mg/dL - Inclusion Criteria for Group 1: diabetic patients 1\. At least one of the following: - Fasting blood sugar ≥ 126mg/dL - Hemoglobin A1c (HgA1c) of \> 6.5% - 2-hour plasma glucose level of \> 200mg/dL during a glucose tolerance test - Receiving treatment with insulin sensitizing drugs (metformin) or sulfonylureas (glipizide, etc.) 3. Inclusion Criteria for Group 2: Non-diabetic patients with insulin resistance (must have both) - Fasting blood glucose of 100-125 mg/dL and - Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score \>3.0 Who Should NOT Join This Trial: 1. Evidence of liver disease other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis 2. Alcohol consumption of more than 12g/d (1 drink) for females or more than 24g/day (2 drinks) for males, for 3 months during the past year 3. Active substance abuse within the past year 4. Prior or ongoing use of injectable insulin 5. Use of oral corticosteroids within the prior 30 days 6. Hospitalization within the past 14 days 7. Known HIV infection 8. HgA1c \>10% 9. Known heart failure of New York Heart Association class 2, 3, or 4 10. Any condition, which in the opinion of the investigator, would impede compliance or hinder the completion of the study 11. History of allergic reactions attributed to compounds of similar chemical or biologic composition to betaine 12. Current use of betaine or S-adenosylmethionine supplements, or refusal to abstain from their use during the study 13. Known cystathionine beta-synthase (CBS) deficiency. 14. Pregnancy or refusal to use birth control measures or breast feeding Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: Inclusion Criteria for all patients: 1. Age 18-75 years 2. A clinical diagnosis of non-alcoholic fatty liver disease. 3. Alanine aminotransferase (ALT) levels ≥60 IU/mL 4. Laboratory tests as defined below: * Platelets \> 100,000/dL * Total bilirubin \< 2 mg/dL * Creatinine \< 1.6 mg/dL * Inclusion Criteria for Group 1: diabetic patients 1\. At least one of the following: * Fasting blood sugar ≥ 126mg/dL * Hemoglobin A1c (HgA1c) of \> 6.5% * 2-hour plasma glucose level of \> 200mg/dL during a glucose tolerance test * Receiving treatment with insulin sensitizing drugs (metformin) or sulfonylureas (glipizide, etc.) 3. Inclusion Criteria for Group 2: Non-diabetic patients with insulin resistance (must have both) * Fasting blood glucose of 100-125 mg/dL and * Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score \>3.0 Exclusion Criteria: 1. Evidence of liver disease other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis 2. Alcohol consumption of more than 12g/d (1 drink) for females or more than 24g/day (2 drinks) for males, for 3 months during the past year 3. Active substance abuse within the past year 4. Prior or ongoing use of injectable insulin 5. Use of oral corticosteroids within the prior 30 days 6. Hospitalization within the past 14 days 7. Known HIV infection 8. HgA1c \>10% 9. Known heart failure of New York Heart Association class 2, 3, or 4 10. Any condition, which in the opinion of the investigator, would impede compliance or hinder the completion of the study 11. History of allergic reactions attributed to compounds of similar chemical or biologic composition to betaine 12. Current use of betaine or S-adenosylmethionine supplements, or refusal to abstain from their use during the study 13. Known cystathionine beta-synthase (CBS) deficiency. 14. Pregnancy or refusal to use birth control measures or breast feeding

Treatments Being Tested

DIETARY_SUPPLEMENT

Betaine (trimethyglycine)

Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.

Locations (1)

VA Long Beach Healthcare System
Long Beach, California, United States